ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2023
The association of donor hepatitis C virus infection with 3-year kidney transplant outcomes in the era of direct-acting antiviral medications.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Sex, Drugs, and the Language of Donor Narratives: Associations With Kidney Acceptance.Transplantation direct · 2026Article
- Equitable Donor Assessment Model of Deceased Donor Kidney Quality.Kidney international reports · 2026Article
- Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection.Kidney international · 2025Article
- Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient.Kidney medicine · 2025Article
- Outcomes of High Kidney Donor Profile Index Hepatitis C Nucleic Acid Testing Positive Kidneys are Equivalent to Matched Hepatitis C Nucleic Acid Testing Negative Kidneys.Transplantation direct · 2025Article
- Optimizing kidney allocation: challenges and solutions.Current opinion in organ transplantation · 2025Review
- Multivariable Predictors of Poorer Renal Function Among 1119 Deceased Donor Kidney Transplant Recipients During the First Year Post-Transplant, With a Particular Focus on the Influence of Individual KDRI Components and Donor AKI.Clinical transplantation · 2025Article
- Risk of Cytomegalovirus Viremia Following Transplantation of Hepatitis C-Viremic Donor Kidneys Into Uninfected Recipients: A Multi-Center Retrospective Cohort Study.Transplant infectious disease : an official journal of the Transplantation Society · 2025Article
- Twelve-month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Time to reconsider the role of donor hepatitis C status in the Kidney Donor Risk Index.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine the effect of donor hepatitis C virus (HCV) infection on kidney transplant (KT) outcomes in the era of direct-acting antiviral (DAA) medications, we examined 68,087 HCV-negative KT recipients from a deceased donor between March 2015 and May 2021. A Cox regression analysis was used to estimate adjusted hazard ratios (aHRs) of KT failure, incorporating inverse probability of treatment weighting to control for patient selection to receive an HCV-positive kidney (either nucleic acid amplification test positive [NAT+, n = 2331] or antibody positive (Ab+)/NAT- [n = 1826]) based on recipient characteristics. Compared with kidney from HCV-negative donors, those from Ab+/NAT- (aHR = 0.91; 95% confidence interval [CI], 0.75-1.10) and HCV NAT+ (aHR = 0.89; 95% CI, 0.73-1.08) donors were not associated with an increased risk of KT failure over 3 years after transplant. Moreover, HCV NAT+ kidneys were associated with a higher 1-year estimated glomerular filtration (63.0 vs 61.0 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.